



**THE FOUNDATION
FOR SECURE
MARKETS**

#45040

DATE: MAY 16, 2019

**SUBJECT: ADJUSTED AXOVANT GENE THERAPIES LTD. – CASH IN LIEU
SETTLEMENT
ADJUSTED OPTION SYMBOL: AXGT1**

Adjusted Axovant Gene Therapies options were adjusted on May 8, 2019 (See OCC Information Memo #45001). The new deliverable became 1) 12 Axovant Gene Therapies Ltd. (AXGT) Common Shares, and 2) Cash in lieu of 0.5 fractional AXGT Shares. Only settlement of the cash portion of AXGT1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$6.94 per whole AXGT share will be used to determine the cash in lieu amount. Accordingly, the cash in lieu amount is:

$$0.5 \times \$6.94 = \$3.47 \text{ per AXGT1 Contract}$$

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of May 8, 2019 through May 16, 2019 to deliver the appropriate cash amount.

Terms of the AXGT1 options are as follows:

New Deliverable Per Contract: 1) 12 Axovant Gene Therapies Ltd. (AXGT) Common Shares
2) \$3.47 Cash

STRIKE PRICES: Unchanged

CUSIP: AXGT: G0750W203

MULTIPLIER: 100 (i.e., a premium of 1.50 yields \$150)

SETTLEMENT

The AXGT component of AXGT1 exercise/assignment activity from May 8, 2019 through May 15, 2019 has settled through National Security Clearing Corporation (NSCC). The \$3.47 cash amount will be settled by OCC.

PRICING

The underlying price for AXGT1 options will be determined as follows:

$$\text{AXGT1} = 0.12 (\text{AXGT}) + 0.0347$$

For example, if AXGT closes at 7.77, the AXGT1 price would be calculated as follows:

$$\text{AXGT1} = 0.12 (7.77) + 0.0347 = 0.97$$

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.